India to Saudi Arabia: Budesonide Export Trade Route

The India to Saudi Arabia Budesonide corridor is one of India's established pharmaceutical export routes, with 75 shipments documented worth a combined $28.9M USD. The route is dominated by CIPLA LIMITED, which alone accounts for roughly 98% of all export value, reflecting the consolidated nature of India's budesonide manufacturing sector.

Across 6 active suppliers, the average shipment value stands at $384.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with budesonide's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 23 days port-to-port. The route has recorded an annual growth rate of 32.4%, placing it at rank #12 among India's top budesonide export destinations globally.

On the import side, key buyers of Indian budesonide in Saudi Arabia include TO THE ORDER OF RIYAD BANK, TO THE ORDER OF SAUDI AWWAL BANK, TO SAB and 17 others. TO THE ORDER OF RIYAD BANK is the single largest importer with 9 shipments valued at $25.6M USD.

India's budesonide exports to Saudi Arabia are driven primarily by a handful of large-scale manufacturers. CIPLA LIMITED with 54 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 6 active exporters signals a competitive but concentrated market — buyers in Saudi Arabia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA LIMITED, CIPLA LIMITED , DHEER HEALTH CARE PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $384.9K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as pulmirema respules 0.25mg/ml(budesonideinhalation suspension 0.5mg/2ml) (6912 packx12x5=414720 nos)(2 ml) and pulmirema respules 0.25mg/ml (budesonide inhalation suspension 0.5mg/2ml) (6,888 pack x 12x5=413280 nos)(2ml), suggesting that buyers in Saudi Arabia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, TO THE ORDER OF RIYAD BANK is the largest importer with 9 shipments worth $25.6M USD — representing 89% of all budesonide imports from India on this route. A total of 20 buyers are active on this corridor.